NCT05687201 · COMPLETED
Effect of Apolipoprotein E on the Prognosis of Patients With Intracerebral Hemorrhage
This observational study is comparing what happens to patients who have a brain bleed (intracerebral hemorrhage) depending on whether they carry the APOE4 gene or not. Researchers are using CT and MRI scans to measure swelling around the bleed and track short-term recovery. There is no experimental treatment being tested — this is a study watching and recording outcomes, not a clinical intervention trial. The phase is unspecified because it is observational research, not a drug or device trial.
You may qualify if
- Relevant diagnosis of supratentorial ICH was confirmed through unenhanced CT scanning.
- Patients were distinguished based on venous blood collection, with the presence of the ApoE-ε4 (ε2/ε4, ε3/ε4, ε4/ε4) gene (ApoE-ε4 genotype) and patients harboring the ApoE-ε3 (ε3/ε3) gene (non-ApoE-ε4 genotype).
You're excluded if
- Patients with infratentorial ICH.
- Patients with ApoE-ε2 (ε2/ε2) based on venous blood collections.
- Younger than 18 years of age.
- ICH caused by trauma, anticoagulation therapy, or antiplatelet therapy.
- Patients admitted to the hospital with diseases that might impact inflammatory responses, such as infective meningitis and systemic infections.
- Patients with previous residual neurological deficits following a stroke.
- Patients with combined tumours, severe liver and kidney dysfunction, cardiac insufficiency.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-08-09